AIMS/HYPOTHESIS: Our aim was to study the risk of renal disease in patients with type 1 diabetes (T1D) and coexisting coeliac disease (CD). METHODS: Individuals with T1D were defined as having a diagnosis of diabetes recorded at ≤30 years of age in the Swedish Patient Register between 1964 and 2009. Individuals with CD were identified through biopsy reports with villous atrophy (Marsh stage 3) from 28 pathology departments in Sweden between 1969 and 2008. We identified 954 patients with both T1D and CD. For each patient with T1D + CD, we selected five age- and sex-matched reference individuals with T1D only (n = 4,579). Cox regression was used to estimate the following risks: (1) chronic renal disease and (2) end-stage renal disease in patients with CD + T1D compared with T1D patients only. RESULTS: Forty-one (4.3%) patients with CD + T1D and 143 (3.1%) patients with T1D only developed chronic renal disease. This corresponded to an HR of 1.43 for chronic renal disease (95% CI 0.94, 2.17) in patients with CD + T1D compared with T1D only. In addition, for end-stage renal disease there was a positive (albeit statistically non-significant) HR of 2.54 (95% CI 0.45, 14.2). For chronic renal disease, the excess risk was more pronounced after >10 years of CD (HR 2.03, 95% CI 1.08, 3.79). Risk estimates were similar when we restricted our cohort to the following T1D patients: (1) those who had an inpatient diagnosis of T1D; (2) those who had never received oral glucose-lowering medication; and (3) those who had not received their first diabetes diagnosis during pregnancy. CONCLUSIONS/ INTERPRETATION: Overall this study found no excess risk of chronic renal disease in patients with T1D and CD. However, in a subanalysis we noted a positive association between longstanding CD and chronic renal disease in T1D.
AIMS/HYPOTHESIS: Our aim was to study the risk of renal disease in patients with type 1 diabetes (T1D) and coexisting coeliac disease (CD). METHODS: Individuals with T1D were defined as having a diagnosis of diabetes recorded at ≤30 years of age in the Swedish Patient Register between 1964 and 2009. Individuals with CD were identified through biopsy reports with villous atrophy (Marsh stage 3) from 28 pathology departments in Sweden between 1969 and 2008. We identified 954 patients with both T1D and CD. For each patient with T1D + CD, we selected five age- and sex-matched reference individuals with T1D only (n = 4,579). Cox regression was used to estimate the following risks: (1) chronic renal disease and (2) end-stage renal disease in patients with CD + T1D compared with T1D patients only. RESULTS: Forty-one (4.3%) patients with CD + T1D and 143 (3.1%) patients with T1D only developed chronic renal disease. This corresponded to an HR of 1.43 for chronic renal disease (95% CI 0.94, 2.17) in patients with CD + T1D compared with T1D only. In addition, for end-stage renal disease there was a positive (albeit statistically non-significant) HR of 2.54 (95% CI 0.45, 14.2). For chronic renal disease, the excess risk was more pronounced after >10 years of CD (HR 2.03, 95% CI 1.08, 3.79). Risk estimates were similar when we restricted our cohort to the following T1D patients: (1) those who had an inpatient diagnosis of T1D; (2) those who had never received oral glucose-lowering medication; and (3) those who had not received their first diabetes diagnosis during pregnancy. CONCLUSIONS/ INTERPRETATION: Overall this study found no excess risk of chronic renal disease in patients with T1D and CD. However, in a subanalysis we noted a positive association between longstanding CD and chronic renal disease in T1D.
Authors: Jonas F Ludvigsson; Eva Andersson; Anders Ekbom; Maria Feychting; Jeong-Lim Kim; Christina Reuterwall; Mona Heurgren; Petra Otterblad Olausson Journal: BMC Public Health Date: 2011-06-09 Impact factor: 3.295
Authors: Luke Forde; Niamh McGrath; Deirdre Devaney; Sami Awadalla; Ciara M McDonnell; Nuala P Murphy Journal: Ir J Med Sci Date: 2018-05-31 Impact factor: 1.568
Authors: Jonas F Ludvigsson; Timothy R Card; Katri Kaukinen; Julio Bai; Fabiana Zingone; David S Sanders; Joseph A Murray Journal: United European Gastroenterol J Date: 2015-04 Impact factor: 4.623
Authors: Katherine V Williams; Christina L Cristaldi; Rachel G Miller; Vincent C Arena; Ingrid Libman; Yihe Huang; Dorothy J Becker; Trevor J Orchard Journal: J Clin Endocrinol Metab Date: 2018-10-01 Impact factor: 5.958
Authors: Jonas F Ludvigsson; Tim Card; Paul J Ciclitira; Gillian L Swift; Ikram Nasr; David S Sanders; Carolina Ciacci Journal: United European Gastroenterol J Date: 2015-04 Impact factor: 4.623
Authors: Norelle R Reilly; Benjamin Lebwohl; Kaziwe Mollazadegan; Karl Michaëlsson; Peter H R Green; Jonas F Ludvigsson Journal: J Pediatr Date: 2015-11-14 Impact factor: 4.406
Authors: Farid H Mahmud; Emilia N De Melo; Karima Noordin; Esther Assor; Kamaljeet Sahota; Jolie Davies-Shaw; Ernest Cutz; Gino Somers; Margaret Lawson; David R Mack; Patricia Gallego; Charlotte McDonald; Melanie D Beaton; Kevin Bax; Fred Saibil; Jeremy Gilbert; Susan Kirsch; Bruce A Perkins; Maria Cino; Eva Szentgyorgyi; Dror Koltin; Amish Parikh; Geetha Mukerji; Andrew Advani; Olivia Lou; Margaret A Marcon Journal: BMJ Open Date: 2015-05-11 Impact factor: 2.692
Authors: Sjoerd F Bakker; Maarten E Tushuizen; Boudewina M E von Blomberg; Hetty J Bontkes; Chris J Mulder; Suat Simsek Journal: Diabetol Metab Syndr Date: 2016-07-29 Impact factor: 3.320